Sulpiride
PreclinicalSmall molecule
Sulpiride is one of 79 small molecule programs targeting Cognition. It is currently in Preclinical.
3
Indications
8
Total Trials
0
Active Trials
78
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
85 competitors in Cognition
#DrugCompanyPhaseTrials
1Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Xarelto
WWim Janssens
Approved
Neurontin
VViatris Specialty LLC
Approved
Duragesic
CCephalon
Approved
Ambien
PPurdue Pharma LP
Approved
Osmitrol
BB. Braun Medical Inc.
Approved
Namenda
AbbViePhase 3
Nuplazid
AACADIA Pharmaceuticals Inc.
Phase 2
Remimazolam Tosilate
FFujian Shengdi Pharmaceutical Co., Ltd.
Phase 3
Psilocybin
COMPASS PathwaysPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Drug Monitoring1 trial
Therapeutic Drug Monitoring and Pharmacokinetic Compartmental Analysis of Sulpiride After Oral Administration to Healthy Volunteers
Completed·—·N/A·NCT01777685·16 enrolled
Mood1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Sulpiride. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- PPhilipps University Marburg